Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Richard T. Cummings

A Proprotein Convertase Subtilisin-Like/Kexin Type 9 (PCSK9) C-Terminal Domain Antibody Antigen-Binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2010English

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2016English

Related publications

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2016English

Cost Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 (PCSK9) Inhibitors

Cardiovascular Disorders and Medicine
2019English

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke

Circulation. Genomic and precision medicine
GeneticsCardiovascular MedicineCardiology
2018English

Lipoprotein(a) and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Clinical Research in Cardiology Supplements
Nuclear MedicineRadiologyMolecular BiologyStructural BiologyImagingMedicine
2019English

Lipoprotein(a) and Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2018English

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Deficiency Is Protective Against Venous Thrombosis in Mice

Scientific Reports
Multidisciplinary
2017English

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Alzheimer’s Disease: A Genetic and Proteomic Multi-Cohort Study

PLoS ONE
Multidisciplinary
2019English

Management of Patients Eligible for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals

Global and Regional Health Technology Assessment
Health Policy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy